Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Eur Urol. 2009 Apr 3;57(4):622–630. doi: 10.1016/j.eururo.2009.03.077

Table 2.

Failure-free survival stratified by D’Amico et al [10] clinical risk stratification and ultrasensitive prostate-specific antigen (USPSA) level

Free of failure*, %
USPSA Preoperative risk category Total n Recurred within 5 yr, n 1 yr 2 yr 3 yr 4 yr 5 yr
Undetectable Low 164 10 98.2 97.6 96.8 92.6 90.9
Intermediate 206 19 96.6 94.7 92.4 90.9 88.7
High 86 22 96.5 86.0 82.2 74.7 70.7
Detectable Low 27 3 92.6 88.9 88.9 88.9 88.9
Intermediate 25 11 92.0 80.0 67.3 57.7 51.9
High 17 7 70.6 58.8 58.8 58.8 58.8

PSA = prostate-specific antigen.

*

Failure defined as two consecutive PSA values ≥0.2 ng/ml or secondary treatment.